News|Articles|January 25, 2007

FDA Creates Office of the Chief Medical Officer, Announces Staff Changes

The US Food and Drug Administration announced the creation of the Office of the Chief Medical Officer as well as two important staff changes at the agency.

Rockville, MD (Jan. 19)-The US Food and Drug Administration (www.fda.gov) announced the creation of the Office of the Chief Medical Officer as well as two important staff changes at the agency.

Deputy Commissioner Janet Woodcock will step into the newly created position of chief medical officer. In this post, she will collaborate with FDA Commissioner Andrew C. von Eschenbach to plan, organize, direct, staff, coordinate, control, and evaluate the agency’s scientific and medical regulatory activities “to achieve the mission of FDA,” according to an official FDA announcement. Said von Eschenbach, “Creation of this office, and position, will better ensure we achieve this mission with the highest scientific quality and effectiveness needed.”

In addition, the agency named John R. Dyer as its deputy commissioner of operations and chief operating officer, a position that will focus on “strengthening the management, business processes, and information technology of the agency.” Before coming to FDA, Dyer served as chief operating officer for the Centers for Medicare and Medicaid Services (Baltimore, MD, www.cms.hhs.gov), where he helped implement the Medicare Modernization Act and led the group’s day-to-day operations.


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.